Novo Nordisk built one of the world's most successful pharmaceutical franchises by turning obesity treatment into a global growth story.

Now the company is trying to convince investors that its next chapter can be just as powerful.

So far, the market is not convinced.

Novo Nordisk shares fell sharply on Monday after the Danish drugmaker presented its long-term strategy and pipeline plans at a capital markets day in London. Shares dropped more than 5% and at one point were down roughly 9% as investors focused on competition, pricing pressure and the company's ability to replace the extraordinary growth generated by Ozempic and Wegovy.

CEO Mike Doustdar is well aware of the problem.

He told investors that competition has reached a level Novo Nordisk has not experienced historically, noting that the company helped create an enormously attractive obesity-treatment market and has since seen virtually every major pharmaceutical company move into the category.

That comment captures Novo's central challenge.

The company helped create the market it now has to defend.

At its capital markets day, Novo announced an ambitious target: launch more than five potential blockbuster medicines by 2030 and generate more than 150 billion Danish crowns, or roughly $23 billion, in risk-adjusted pipeline sales by 2035.

The company also wants to have at least five Phase 3 programs in obesity and diabetes and another five Phase 3 programs across other therapeutic areas.

That represents a broad attempt to diversify beyond its existing GLP-1 franchise.

The need for diversification is becoming increasingly urgent because Novo's current blockbuster drugs face several pressures simultaneously.

Competition is rising.

Pricing power is under scrutiny.

Patients have more options.

And patents protecting semaglutide — the active ingredient behind Ozempic and Wegovy — are expected to expire in major markets in the early 2030s.

That gives Novo several years to build its next generation of products.

But investors are demanding evidence that the pipeline can deliver.

For much of the modern GLP-1 boom, Novo Nordisk and Eli Lilly dominated attention.

That is changing.

Large pharmaceutical companies are developing obesity medicines, oral therapies and next-generation treatments.

That competition could affect market share and pricing.

It could also force companies to move faster.

Doustdar's comments acknowledge the transformation.

Novo once operated in what he described as an environment that could often be viewed as a duopoly.

Now the company is facing competition from pharmaceutical groups of all sizes.

That creates a very different strategic environment.

Novo cannot rely solely on the strength of its existing brands.

It has to continue producing meaningful improvements in effectiveness, convenience, tolerability, dosing and patient access.

One of Novo's biggest strategic bets is moving from injectable GLP-1 treatments into pills.

The company plans to scale manufacturing capacity enough to serve roughly 15 million patients with oral obesity treatments by the end of the decade and aims to reach more than 60 million patients globally by 2030.

The goal is ambitious.

Pills can potentially make obesity treatment easier to distribute and more convenient for some patients.

Novo's oral Wegovy has already generated meaningful demand in the United States.

The company said the pill has reached about seven million prescriptions to date, with roughly 90% of those sales coming through direct cash-pay channels.

That figure is significant because it demonstrates that Novo can generate demand outside traditional insurance structures.

But long-term commercial success will depend on pricing, reimbursement, manufacturing capacity and competition.

The patent issue is central to the entire strategy.

Semaglutide has become one of the most valuable pharmaceutical molecules in the world.

Ozempic and Wegovy helped transform Novo's revenue base.

But blockbuster medicines eventually face generic or biosimilar competition when patents expire, depending on jurisdiction and product.

Novo therefore wants to launch new products well before the current franchise faces its biggest patent-related challenges.

The company's target of more than five blockbuster launches by 2030 is designed around precisely that need.

The question investors are asking is whether those medicines can realistically replace enough of today's growth.

Novo's near-term obesity pipeline includes CagriSema, a combination treatment involving semaglutide and cagrilintide.

The company expects to begin launching CagriSema in early 2027, followed by additional formulations and treatments over subsequent years.

Standalone cagrilintide and higher-dose versions of CagriSema are part of the broader rollout, with zenagamtide also advancing through development.

This gives Novo multiple shots on goal.

But investors are not just looking for a list of potential products.

They want to know how those drugs will perform commercially against increasingly strong competitors.

Pricing may be one of the most important issues in Novo's next phase.

When a market has only a small number of major suppliers, companies can potentially maintain stronger pricing.

As competition expands, pricing pressure can increase.

That can happen even if the overall market continues growing rapidly.

Novo's challenge is therefore not simply to sell more doses.

It needs to defend margins while investing heavily in research, manufacturing and commercial infrastructure.

The company's stated goal is for its adjusted operating margin to remain broadly stable through 2030.

That is important because maintaining profitability while expanding capacity and developing new medicines will require careful capital allocation.

The company is not only changing its drug portfolio.

It has undergone a significant restructuring.

Reuters reported that roughly 13,000 employees have left the company following restructuring efforts, including an initial reduction of 9,000 jobs and an additional 4,000 departures.

Those reductions reflect the scale of the transformation Novo is attempting.

The company must become faster and more efficient while simultaneously increasing research activity.

That can be a difficult combination.

Research organizations often require long development cycles.

Commercial organizations need quick responses to changing markets.

Management is attempting to operate with greater urgency without sacrificing scientific quality.

The company's targets were ambitious.

But they were also long-dated.

Investors looking for clearer near-term growth guidance did not get everything they wanted.

Yahoo Finance reported that Novo came up short in the eyes of some investors because it did not provide more detailed near-term growth targets despite outlining a broad long-term pipeline strategy.

That helps explain the stock reaction.

Markets generally value future growth.

But they also need evidence that the next few years will bridge the gap between today's revenue and tomorrow's pipeline.

A 2035 sales target may be encouraging.

It does not answer every question about 2027 or 2028.

Any discussion of Novo's pipeline eventually returns to Eli Lilly.

Lilly has emerged as a major competitor in obesity treatment and has been aggressively developing its own GLP-1 portfolio.

That changes the competitive landscape.

Novo can no longer assume that strong demand for obesity treatment automatically translates into strong demand for Novo's specific products.

Doctors and patients can increasingly compare options.

That puts more emphasis on clinical outcomes, convenience, tolerability, manufacturing reliability and cost.

The market itself may expand while individual companies fight harder for share.

Despite the investor disappointment, the company retains several major assets.

Its brands are globally recognized.

Its manufacturing expertise is substantial.

Its clinical-development experience in diabetes and obesity is extensive.

Its existing customer base is enormous.

And its pipeline contains multiple potential products.

The company is also targeting treatment for more than 60 million patients globally by 2030, a scale that would represent a substantial expansion of its current reach.

The question is not whether Novo has resources.

It is whether it can deploy those resources quickly enough.

This is another important distinction.

Novo's problem is not necessarily that demand for obesity treatment is disappearing.

Quite the opposite.

Demand remains enormous.

The challenge is that the market has become so attractive that more companies are competing for it.

That means a larger market does not automatically make life easier for the incumbent.

It can increase revenue opportunities while simultaneously increasing competition.

Novo is now trying to stay ahead of that curve.

By 2030, Novo wants more than five potential blockbuster launches.

Before then, it has to execute on clinical development, regulatory submissions, manufacturing expansion and commercial strategy.

That gives investors several milestones to monitor.

Clinical-trial results.

Regulatory decisions.

New product launches.

Patient uptake.

Pricing.

Market share.

And the pace at which oral treatments expand.

Each will provide evidence about whether the company's long-term targets are achievable.

The market reaction does not mean Novo Nordisk has lost its position in obesity medicine.

It means investors are demanding evidence of what comes after the current generation of blockbusters.

That is a very different problem.

The company that once benefited from being one of the few dominant players in obesity treatment is now trying to prove it can thrive in a crowded market of increasingly capable competitors.

Mike Doustdar has identified the core challenge himself.

Competition has changed.

Novo created an attractive market.

Now everybody wants a piece of it.

The company's next chapter will depend on whether it can turn its enormous research pipeline into enough new medicines, enough patients and enough revenue to replace the growth generated by Ozempic and Wegovy.

For now, Wall Street is asking for proof.

And Monday's selloff shows just how valuable that proof has become.